Have a feature idea you'd love to see implemented?
Let us know!
ALXO Alx Oncology Holdings Inc
Price (delayed)
$1.62
Market cap
$85.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.97
Enterprise value
$79.18M
ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system.
Highlights
The EPS is up by 18% since the previous quarter and by 17% year-on-year
The quick ratio has declined by 15% year-on-year but it has increased by 13% since the previous quarter
ALXO's net income is up by 12% since the previous quarter but it is down by 3.5% year-on-year
Alx Oncology Holdings's equity has decreased by 19% YoY and by 14% QoQ
The debt has grown by 2.7% year-on-year
Key stats
What are the main financial stats of ALXO
Market
Valuations
Earnings
Shares outstanding
52.74M
Market cap
$85.44M
Enterprise value
$79.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$151.16M
EBIT
-$149.44M
EBITDA
-$148.58M
Free cash flow
-$130.08M
Per share
Balance sheet
Liquidity
EPS
-$2.97
EPS diluted
-$2.97
Free cash flow per share
-$2.47
Book value per share
$2.6
Revenue per share
$0
TBVPS
$3.52
Total assets
$185.72M
Total liabilities
$48.91M
Debt
$9.84M
Equity
$136.81M
Working capital
$123.56M
Debt to equity
0.07
Current ratio
4.82
Quick ratio
4.59
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-70.7%
Return on equity
-93%
Return on invested capital
-87%
Return on capital employed
-97.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALXO stock price
How has the Alx Oncology Holdings stock price performed over time
Intraday
9.46%
1 week
11.72%
1 month
33.88%
1 year
-87.69%
YTD
-89.12%
QTD
-10.99%
Financial performance
How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$159.88M
Net income
-$151.16M
Gross margin
N/A
Net margin
N/A
ALXO's net income is up by 12% since the previous quarter but it is down by 3.5% year-on-year
ALXO's operating income is up by 11% QoQ but it is down by 3.5% YoY
Growth
What is Alx Oncology Holdings's growth rate over time
Valuation
What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
0.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% since the previous quarter and by 17% year-on-year
The price to book (P/B) is 81% less than the 5-year quarterly average of 3.2 and 75% less than the last 4 quarters average of 2.5
Alx Oncology Holdings's equity has decreased by 19% YoY and by 14% QoQ
Efficiency
How efficient is Alx Oncology Holdings business performance
ALXO's return on equity is down by 41% year-on-year but it is up by 8% since the previous quarter
The return on assets has declined by 27% year-on-year but it is up by 8% since the previous quarter
ALXO's return on invested capital is down by 23% year-on-year but it is up by 8% since the previous quarter
Dividends
What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALXO.
Financial health
How did Alx Oncology Holdings financials performed over time
The total assets has declined by 16% year-on-year and by 13% since the previous quarter
The quick ratio has declined by 15% year-on-year but it has increased by 13% since the previous quarter
The debt is 93% smaller than the equity
Alx Oncology Holdings's equity has decreased by 19% YoY and by 14% QoQ
Alx Oncology Holdings's debt to equity has increased by 17% from the previous quarter and by 17% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.